Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Esperion Therapeutics, Inc. (ESPR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/01/2023 8-K Quarterly results
05/09/2023 8-K Quarterly results
Docs: "Esperion Reports First Quarter 2023 Financial Results – U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y&#59; New to Brand Prescriptions Grew 56% Q/Q –"
05/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Case 1:23-cv-02568-ER Document 19 Filed 05/04/23 Page 1 of 37"
03/27/2023 8-K Quarterly results
03/22/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Form of Common Stock Purchase Warrant",
"Form of Pre-Funded Common Stock Purchase Warrant",
"Opinion of Goodwin Procter LLP",
"Form of Securities Purchase Agreement",
"Form of Warrant Amendment Agreement",
"Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules",
"Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules"
03/15/2023 8-K Other Events  Interactive Data
03/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/06/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Landmark CLEAR Outcomes Study Demonstrates NEXLETOL Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin"
01/09/2023 8-K Quarterly results
11/23/2022 8-K Quarterly results
11/16/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
09/20/2022 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "CERTIFICATE OF VALIDATION OF CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ESPERION THERAPEUTICS, INC."
08/02/2022 8-K Quarterly results
Docs: "Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update – Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial&#59; On Track for Topline Results 1Q 2023 –"
06/13/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
04/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Esperion Announces the Appointment of Stephen Rocamboli to"
03/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/01/2022 8-K Quarterly results
02/22/2022 8-K Quarterly results
Docs: "Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update – Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 –"
01/11/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update – Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events Accumulation in 2H 2022&#59; Achieved 85% MACE Accumulation in December –"
01/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT",
"Esperion Appoints Benjamin O. Looker as General Counsel – Addition to management team brings experienced strategic legal counsel as Company nears pivotal milestones –"
12/07/2021 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update – Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth –"
11/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors ANN ARBOR, Mich., November 1, 2021"
10/25/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Esperion Therapeutics, Inc. 4.00% Convertible Senior Subordinated Notes due 2025 Each undersigned investor , hereby agrees to exchange, with Esperion Therapeutics, Inc., a Delaware corporation , certain 4.00% Convertible Senior Subordinated Notes due 2025, CUSIP 29664W AA3 for shares of the Company’s common stock, $0.001 par value per share , pursuant to this exchange agreement . Each Exchanging Investor understands that the exchange is being made without registration of the offer or sale of the Shares under the Securities Act of 1933, as amended , or any securities laws of any state of the United States or of any other jurisdiction pursuant to Section 4 of the Securities Act, and that each Exchanging Investor participating in the Exchange is required to be an institutional “accredited inv...",
"ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock"
10/18/2021 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Other Events, Financial Stat...
Docs: "ESPERION Announces Plan for Transformative Long-Term Growth"
08/03/2021 8-K Quarterly results
Docs: "ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update – U.S. Net Product Revenue of NEXLETOL® Tablets and NEXLIZET® Tablets Grew 67% Sequentially to $10.6 Million –"
06/28/2021 8-K Quarterly results
05/28/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy